Clinical Trial

Predictive Signature of Benralizumab Response

Study acronym: BENRAPRED
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients. This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2020-09-21; most recent amendment 2024-04-25.
Status change: Not Yet Recruiting → Recruiting 2021-10-14
Trial Details
NCT Number NCT04565483
Lead Sponsor Nantes University Hospital
Collaborators: AstraZeneca, Ministère de la Santé - France
Conditions Asthma; Eosinophilic, Severe Asthma
Enrollment 220 participants
Start Date 2021-10-11
Primary Completion 2026-10 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-04-26